INDEX / DIRECTORY / TEVA PHARMACEUTICALS / DIGITAL

Teva Pharmaceuticals DIGITAL

DIGITAL INFRASTRUCTURE AUDIT UPDATED 2026-10-22
Digital Score 0.00 /10 A Teva Pharmaceuticals - Complicity Index 811
Digital 0.00

Evidence-only forensic audit. Scoring happens downstream - see the main dossier for the composite assessment.

Company suggestions now arrive faster than we can research them. We need £200 a month in donations to cover our research tools and hosting. Support OpenIntel →

Research updated: 22 October 2026

Enterprise Technology Stack & Vendor Relationships

Teva’s February 2025 cybersecurity disclosure describes third-party consultants, service providers, cybersecurity monitoring and vendor due-diligence procedures. The disclosure does not identify Check Point, Wiz, SentinelOne, CyberArk, NICE, Verint, Claroty or Palo Alto Networks as Teva suppliers. No public evidence identified of a direct licensing, subscription or integration relationship with these named Israeli-origin cybersecurity vendors. The disclosure identifies an enterprise cybersecurity programme but does not establish which specific products support its critical infrastructure 1.

Teva announced on 21 October 2020 that its Digihaler digital-inhaler portfolio was powered by Amazon Web Services, with Onica acting as a technology implementation partner. The collaboration involved cloud infrastructure for digital respiratory-care services. The announcement establishes a specific healthcare technology relationship; no public evidence identified in this announcement of a Teva contract to provide AWS infrastructure to Israeli state institutions. The current operational status of the original arrangement was not independently established in this expansion 2.

In 2017, Computer Weekly documented Teva’s implementation of SAP SuccessFactors Employee Central and Qlik analytics in a global cloud HR transformation covering more than 60 countries. This historical deployment involved a significant investment in workforce and HR data systems. [pre-2020] The reviewed evidence does not independently confirm the current deployment scope or whether the original products remain in use unchanged 3.

Teva’s global pharmacovigilance privacy notice, last updated May 2024, expressly identifies Accenture as an India-based data-processing provider responsible for data entry, administration and data cleansing for a limited portion of the pharmacovigilance database. The notice also describes Teva pharmacovigilance administration and support in Israel and India. This constitutes a documented technology-processing and outsourcing relationship involving sensitive healthcare information 4.

An interview originally published in December 2020 identifies Ilan Abadi as Teva’s global CISO and describes his previous cybersecurity positions at Ness Technologies and the Israel National Police. The source establishes his professional experience but does not demonstrate Teva procurement from either former employer or identify a Unit 8200 affiliation. No specific enterprise vendor relationship can be inferred from those prior positions 5.

No public evidence identified that Teva’s implementation partners required or deployed the Israeli-origin security products named in the research checklist. No public evidence identified of the scale of any undisclosed Israeli-origin software deployment within Teva’s corporate network, cloud platforms or contact-centre infrastructure 1, 4.

Surveillance, Biometrics & Retail Technology

No public evidence identified of Teva deploying Israeli-origin facial-recognition, biometric-identification, gait-analysis or frictionless-retail technology supplied by Trigo, BriefCam, AnyVision/Oosto, Trax or comparable providers. The reviewed corporate technology disclosures concern pharmaceutical manufacturing, healthcare services, cybersecurity, clinical information and digital transformation 1, 2, 6.

No public evidence identified of Teva using Israeli-origin predictive-policing software, workforce surveillance, sentiment-monitoring technology or social-media intelligence platforms. Its published cybersecurity programme describes security monitoring but does not name the surveillance vendors investigated 1.

No public evidence identified of these technologies being deployed indirectly through a managed security provider, systems integrator or bundled enterprise platform. The available disclosures do not provide a complete inventory of Teva’s internal security and monitoring products 1.

No independently verified evidence identified in this expansion that Teva’s reported medical facial-analysis research involved biometric surveillance, police identification or monitoring of occupied-territory populations 6.

Cloud Infrastructure, Data Residency & Sovereign Cloud Participation

Teva Pharmaceutical Industries Ltd. and its subsidiaries publish privacy notices confirming international processing of personal data. Teva’s global website privacy notice identifies Israeli group companies as recipients or providers of IT support, hosting and other business services. The Teva UK privacy notice likewise identifies Israel among countries where group companies may process personal information. These are company disclosures of cross-border processing arrangements involving Israeli jurisdiction 7, 8.

Argentina corporate attribution, verified October 2026: Teva Pharmaceuticals operates an official Argentina website at teva.com.ar. Its website privacy policy identifies Ivax Argentina S.A. and the global Teva group. The policy describes international transfers of personal data, including transfers to Israel, the European Union and the United States. These disclosures establish a Teva Pharmaceuticals Argentina privacy policy and an explicit Israeli destination within the company’s cross-border data-processing framework 9.

The Argentina pharmacovigilance privacy notice identifies Teva Pharmaceutical Industries Ltd. and its local affiliate Ivax Argentina S.A. The notice gives Ivax Argentina’s address as Juan José Castelli 6701, Villa Adelina, Buenos Aires, Argentina. Its stated effective date is August 2024. The notice therefore directly attributes the policy to the pharmaceutical group and identifies the local data controller 10.

Teva’s global medical-information consent page independently identifies Teva Pharmaceutical Industries Ltd. and an applicable local affiliate for Argentina. Its Argentina-specific consent statement describes international personal-data transfers associated with medical inquiries and references the Argentine personal-data protection framework 11.

The Argentina website’s terms and conditions specify Israeli law and Tel Aviv courts for disputes concerning those website terms. This documents a contractual choice-of-law and jurisdiction provision for the Argentine website; it does not establish the physical storage location of its users’ data 12.

Correction of previous attribution: The earlier audit cited a privacy policy from tevaag.com as evidence of the Teva Pharmaceuticals Argentina privacy policy. That source belongs to TEVA Holdings LLC, an agricultural-products business. It is unrelated to the pharmaceutical privacy notices discussed here. The present finding relies on the authenticated pharmaceutical company sources at teva.com.ar and tevapharm.com 9, 10, 11.

Teva’s global pharmacovigilance privacy notice, last updated May 2024, identifies the United States as the location of its pharmacovigilance database. It identifies teams in Israel and India as administering and supporting the database, and Accenture in India as a processor handling a limited part of the information. The same notice places the medical-inquiries database with a third-party provider in Europe and the quality-complaints database in the United States 4.

The Argentina pharmacovigilance notice, effective August 2024, independently describes the United States as the location of Teva’s pharmacovigilance databases and Israel and India as locations of administration and support. It identifies Accenture’s India-based processing role. The Argentina notice therefore corroborates the global company’s cross-border pharmacovigilance arrangements using a locally attributable primary source 10.

Historical hosting distinction: A Teva Israel pharmacovigilance notice effective November 2020 stated that its pharmacovigilance databases, including the global database, were hosted in Israel by Teva. [pre-2020: not applicable; source effective in 2020.] This is historical documentation of an earlier hosting arrangement. The later May and August 2024 company notices identify US hosting. The reviewed records do not specify the date of any migration or independently establish the present physical infrastructure configuration 13, 4, 10.

Teva’s documented processing arrangements involve patient-safety reports, medical inquiries and product complaints. The company describes cross-border processing and administration involving Israel. The precise categories of accessible personal data, individual employee access permissions and technical safeguards cannot be independently determined from the published policies alone 10, 4, 8.

The August 2024 Argentina policy and the subsequently published Teva UK privacy notice document international processing arrangements after 19 July 2024. The continuing availability of these notices provides evidence of company-published processing arrangements following that date, but the notices do not establish particular data-access events, contract renewal dates or individual transfers after November 2024 10, 7.

No public evidence identified of Teva operating a commercial data-centre business, providing sovereign-cloud infrastructure to Israeli government agencies or participating as a contractual supplier in Project Nimbus. The documented AWS Digihaler relationship concerns Teva’s digital healthcare products and does not itself establish participation in the Israeli government’s Nimbus programme 2.

No public evidence identified that Teva markets government data-residency, sovereign-cloud or resilience infrastructure services to the IDF, Ministry of Defence or intelligence agencies. Its published data-processing arrangements describe its pharmaceutical and healthcare operations 4, 8.

Defence, Intelligence & Security Sector Technology Relationships

No public evidence identified of direct IT infrastructure, digital surveillance, cybersecurity, cloud-hosting or software contracts between Teva and the Israeli Ministry of Defence, IDF or intelligence agencies. The identified technology partnerships concern pharmaceutical digital services, enterprise systems and biomedical research 2, 14, 6.

Declassified UK’s investigation documented relationships between Teva and Israeli military-support initiatives, including the Thank Israeli Soldiers organisation and historical reservist-support programmes. These are reported corporate-support activities. The article does not establish that Teva supplied digital surveillance, cloud infrastructure or military intelligence software through those programmes 15.

The same investigation describes the involvement of Teva personnel in IDF reserve service following October 2023. Individual military service and employee-support policies do not independently establish a company contract for offensive cybersecurity or military digital systems 15.

No public evidence identified of Teva developing, licensing, maintaining or selling zero-day exploitation systems, spyware, offensive cyber capabilities or digital weapons to Israeli security bodies 15, 1.

No public evidence identified of Teva general-purpose pharmaceutical software being supplied for Israeli military surveillance operations, intelligence collection or law-enforcement monitoring in the occupied Palestinian territories 2, 6.

AI, Algorithmic & Autonomous Systems

Teva was identified as a founding pharmaceutical partner in AION Labs, an Israeli venture studio focused on AI-enabled drug discovery and development. AWS described the collaboration with pharmaceutical partners, venture funds and biomedical research organisations in its launch material. The venture studio’s publicly described functions involve civilian pharmaceutical research and therapeutic development 14.

A July 2026 announcement identified Teva among the industry partners in the Israel BioToken Factory Initiative, a national biological AI infrastructure programme involving NVIDIA, Sheba Medical Center, Israeli universities and biotechnology companies. The reported NIS 70 million programme concerns biological foundation models, drug discovery and personalised medicine 16.

The BioToken initiative is described as a research and development consortium involving public innovation support and private industry participation. The public announcement establishes Teva’s named participation but does not disclose Teva’s individual capital contribution, contractual rights, dataset ownership or access to specific patient records 16.

On 19 November 2025, Teva announced Teva Rise, an open-innovation platform inviting technology companies and startups to work on AI, smart manufacturing, digital health, biotechnology and pharmaceutical operations. Its first cohort covered seven challenges across research, manufacturing, supply chains, commercial operations and medical affairs. The announcement explicitly included Israel among the markets in which solutions could be tested or scaled 6.

No public evidence identified that the AION Labs, BioToken or Teva Rise programmes used intercepted communications, intelligence-surveillance datasets, military biometric records or datasets obtained from populations in occupied territories. The cited programme descriptions identify biomedical, pharmaceutical and manufacturing applications 14, 6, 16.

No public evidence identified of Teva providing autonomous target-generation software, automated military threat identification, kinetic targeting systems or autonomous tracking products to Israeli military or security forces. The publicly documented AI initiatives concern pharmaceutical research and industrial transformation 14, 6, 16.

Technology Ecosystem & R&D Footprint

Teva’s documented technology ecosystem includes Israeli pharmaceutical AI research through AION Labs, the Israel BioToken Factory Initiative and Teva Rise. The first two establish participation in Israeli biomedical AI initiatives; Teva Rise establishes an international innovation platform that expressly includes Israel among its operating and potential deployment markets 14, 6, 16.

Teva’s November 2025 Rise announcement describes a global approach through which startups and technology suppliers can submit solutions to operational challenges. The stated scope includes R&D, manufacturing, supply chains, commercial processes and medical affairs. The announcement documents a company-organised pathway for technology-provider engagement, although the exact commercial terms for individual startups are undisclosed 6.

Teva’s January 2026 financial announcement reports 2025 revenue of approximately $17.3 billion and identifies ongoing pharmaceutical product and research priorities. The announcement establishes continued operations into 2026 but does not independently identify the individual software vendors serving Israeli facilities 17.

Former Teva executive Eyal Desheh served as Teva’s CFO from 2008 to 2017. MigVax’s 2020 appointment announcement describes his earlier executive roles at Teva and Check Point Software Technologies. These are documented individual career relationships rather than direct Teva supplier contracts 18.

Tevel Aerobotics identifies Desheh as its chairman. MigVax’s 2020 appointment announcement likewise describes his previous Teva and Check Point executive experience. The evidence documents his post-Teva corporate roles but does not establish that Teva Pharmaceutical Industries acquired equity stakes in those businesses or procured their technology 19, 18.

No public evidence identified of a verified Teva acquisition of an Israeli offensive-cybersecurity, surveillance or military-AI company. The reviewed technology partnerships instead involve biomedical AI, digital healthcare and pharmaceutical innovation 14, 6, 16.

No public evidence identified of patents or co-development agreements between Teva and Israeli military-intelligence laboratories involving spyware, signals intelligence, offensive cyber tools or autonomous military targeting. The documented programmes concern drug discovery and related biomedical research 14, 16.

Civil Society Scrutiny & Regulatory History

Who Profits lists Teva Pharmaceutical Industries under economic exploitation and the Palestinian captive market. Its company profile explicitly states that the underlying information was valid until 22 July 2012. [pre-2020] Its historical findings describe pharmaceutical-market access and restrictions affecting Palestinian pharmaceutical businesses. These claims should be understood as civil-society research concerning pharmaceutical market structures, without inferring an undisclosed technology or surveillance contract 20.

AFSC Investigate also identifies Teva in relation to the Palestinian pharmaceutical market. Its published profile concerns the company’s pharmaceutical operations and market position. The profile does not independently identify a Teva digital-surveillance contract or a Teva-operated government cloud platform 21.

Declassified UK investigated Teva’s relationships with Israeli military-support initiatives and its position within UK pharmaceutical supply chains. The investigation concerns company conduct, medicine supply and reported military-support activities; no independently verified supply of surveillance platforms or offensive cyber systems was established from the article 15.

On 4 March 2024, activists protested outside a Teva facility in the United Kingdom, calling for a boycott of Teva pharmaceuticals. The published account describes the protest and its opposition to the company’s involvement in the Israeli economy and wider political circumstances. The protest was not documented as a challenge to a specific Teva cybersecurity or software contract 22.

On 7 November 2025, Peoples Dispatch reported renewed European solidarity campaigns calling for alternatives to Teva pharmaceutical products. The campaign grounds concerned alleged involvement in the occupation, economic relationships and pharmaceutical purchasing. The report does not provide independently verified evidence of an Israeli military digital-services contract with Teva 23.

The available sources document continuing civil-society criticism of Teva after the ICJ advisory opinion of July 2024 and the ICC arrest warrants issued in November 2024. They do not independently establish that Teva entered, renewed or performed a particular surveillance-technology contract after those dates 15, 23.

No public evidence identified of a regulatory investigation, export-control enforcement action or sanctions proceeding specifically concerning Teva’s supply of cloud infrastructure, surveillance technology, cyber tools or military AI to Israeli state institutions. The technology relationships identified in this audit concern pharmaceutical and healthcare services 1, 2, 14, 6.

No public evidence identified of Teva supplying settlement-specific biometric systems, surveillance networks or digital platforms to Israeli settlements through subsidiaries, resellers or licensees. The historical Who Profits and AFSC material concerns pharmaceutical-market access and should not be interpreted as verification of those technology deployments 20, 21.

Footnotes

  1. https://www.board-cybersecurity.com/annual-reports/tracker/20250205-teva-pharmaceutical-industries-cybersecurity-10k ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  2. https://www.tevausa.com/news-and-media/press-releases/teva-amazon-web-services-and-onica-announce-collaboration-to-support-tevas-digihaler-portfolio/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  3. https://www.computerweekly.com/news/450428023/Teva-Pharmaceuticals-turns-to-cloud-HR-as-it-weathers-difficult-trading-conditions ↩

  4. https://www.tevapharm.com/our-company/leadership-governance/teva-privacy-notice ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  5. https://cybeready.com/hi-5-with-ilan-abadi/ ↩

  6. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-Launches-Rise-A-Global-Open-Innovation-Platform-to-Accelerate-AI-Industry-4-0-Smart-Manufacturing-Digital-Health-and-Biotech-Breakthroughs-for-Pharmas-Biggest-Challenges/default.aspx ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11

  7. https://www.tevauk.com/general-pages/privacy-policy/ ↩ ↩2

  8. https://www.tevapharm.com/our-company/leadership-governance/data-privacy/ ↩ ↩2 ↩3

  9. https://www.teva.com.ar/politica-de-privacidad-sitio-web/ ↩ ↩2

  10. https://www.teva.com.ar/politicas-de-privacidad-farmacovigilancia/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  11. https://www.tevapharm.com/teva-medical-information/countries-consent/ ↩ ↩2

  12. https://www.teva.com.ar/terminos-y-condiciones/ ↩

  13. https://il-hcpprep.tevapharm.com/phv-privacy-policy/ ↩

  14. https://aws.amazon.com/blogs/industries/aws-joins-pharma-and-biotech-leaders-in-launching-aion-labs-to-transform-therapeutics/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  15. https://www.declassifieduk.org/the-israeli-firm-aiding-the-nhs-and-idf/ ↩ ↩2 ↩3 ↩4 ↩5

  16. https://www.synbiobeta.com/read/the-israel-innovation-authority-to-invest-approximately-nis-70-million-in-national-infrastructure-for-ai-models-based-on-biological-data ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  17. https://www.tevapharm.com/news-and-media/latest-news/teva-innovative-portfolio-and-consistent-execution-of-pivot-to-growth-strategy-deliver-third-consecutive-/ ↩

  18. https://www.prnewswire.com/il/news-releases/migvax-appoints-eyal-desheh-former-teva-check-point-executive-as-chairman-301072256.html ↩ ↩2

  19. https://www.tevel-tech.com/eyal-desheh-about/ ↩

  20. https://www.whoprofits.org/companies/company/4212?teva-pharmaceutical-industries= ↩ ↩2

  21. https://investigate.afsc.org/company/teva-pharmaceutical-indus ↩ ↩2

  22. https://freedompress.org.uk/2024/03/04/ongoing-protest-at-israeli-pharmaceutical-factory/ ↩

  23. https://peoplesdispatch.org/2025/11/07/europes-palestine-solidarity-movement-strengthens-call-to-boycott-israeli-pharmaceutical-company-teva/ ↩ ↩2